Home / Business and Economy / Cava Soars on Rosy 2026 Outlook
Cava Soars on Rosy 2026 Outlook
25 Feb
Summary
- Cava Group forecasts 3%-5% sales growth for established restaurants in 2026.
- Stripe is reportedly considering acquiring parts or all of PayPal.
- Novo Nordisk's weight-loss drug trial results prompt calls for strategic diversification.
Cava Group reported robust fourth-quarter sales and presented an optimistic outlook for 2026, projecting 3% to 5% sales expansion for its established restaurants. This performance exceeds that of its fast-casual competitors and defies expectations of an economic slowdown. The company attributes this success to price increases and customers choosing more premium options, even as store visits have declined.
In other market news, shares of PayPal Holdings Inc. saw a notable increase following reports that Stripe is exploring the possibility of acquiring all or part of the payment company. While these discussions are in their early stages and a transaction is not guaranteed, the news significantly impacted PayPal's market value.
Conversely, Novo Nordisk experienced a setback as its next-generation weight-loss drug, CagriSema, yielded disappointing trial results. This outcome has triggered calls from some investors for the pharmaceutical giant to diversify its strategy beyond diabetes and obesity treatments, suggesting exploration into areas like rare diseases, heart disease, or oncology.
